DPP4 and type 2 diabetes mellitus: Sitagliptin, a DPP4 inhibitor was the first commercialized approved for treatment of patients with T2DM in Oct 2006 in USA and in 2007 by the European Medicines Agency (EMA) at a dosage of 100 mg daily39.